TaiwanLegal Representation for Pharmaceuticals in Taiwan
Taiwan's pharmaceuticals market demands a licensed local legal representative before any drug product can be registered or sold. Taevas Global provides compliant, experienced legal representation that satisfies TFDA requirements and accelerates your marke
Six Pillars of Taiwan Pharmaceuticals Intelligence
Our legal representation service for Taiwan pharmaceuticals is built on six interconnected pillars that cover every regulatory, commercial, and compliance dimension of your market entry.
TFDA-Compliant Representation
Taevas Global acts as your appointed local legal representative under Taiwan's Pharmaceutical Affairs Act, satisfying the mandatory requirement for a licensed domestic entity. We hold the registration in your name and manage all official correspondence with the Taiwan Food and Drug Administration on your behalf. This removes the single largest structural barrier for foreign pharmaceuticals manufacturers entering Taiwan.
From Brief to Board-Ready Intelligence
Our four-step engagement model takes you from initial scoping through full legal representative appointment and ongoing compliance management in a structured, transparent process.
Scope and Eligibility Assessment
We begin by reviewing your product portfolio, intended indications, and existing regulatory documentation to confirm eligibility for Taiwan market entry. This assessment identifies any gaps in your dossier, flags products that may require additional clinical or bioequivalence data under TFDA standards, and clarifies the correct application pathway for each product. You receive a written scope summary and a proposed engagement plan within two business days.
The assessment covers product classification under Taiwan's Pharmaceutical Affairs Act, applicable registration category (new drug, generic, OTC), required documentation checklist, estimated TFDA review timelines, and preliminary cost projections for government fees and translation. This gives your leadership team a clear picture of the investment and timeline before committing to the full engagement.
Taiwan Pharmaceuticals Market at a Glance
NHI as the Commercial Gateway
Taiwan's National Health Insurance program covers over 99 percent of the population and reimburses the majority of pharmaceutical spending, making NHI listing the critical commercial milestone for any foreign drug product. Products not listed on the NHI reimbursement schedule face severely limited market access regardless of their TFDA approval status. Understanding the NHI listing process and pricing negotiation dynamics is therefore inseparable from the registration strategy.
TFDA's Strengthened Post-Market Surveillance
TFDA has progressively tightened post-market surveillance requirements in recent years, including mandatory pharmacovigilance system audits for foreign manufacturers and stricter timelines for adverse event reporting. Foreign legal representatives bear direct regulatory responsibility for these obligations, making the choice of representative a compliance-critical decision. Companies that underestimate post-market requirements frequently face license suspension or recall actions.
Generics and Biosimilars Driving Growth
Taiwan's pharmaceuticals market is increasingly driven by generic drug substitution policies and a growing biosimilars pipeline, with the government actively encouraging substitution to manage NHI expenditure. Foreign generics manufacturers have significant opportunities to capture market share if they can navigate the bioequivalence data requirements and price competitively within NHI reimbursement bands. Biosimilar approvals are handled under a dedicated TFDA pathway that requires specific comparability data packages.
Digital Health and Precision Medicine Integration
Taiwan is investing heavily in precision medicine and digital health infrastructure, including the Taiwan Precision Medicine Initiative and integration of genomic data into clinical practice guidelines. Pharmaceutical companies developing companion diagnostics or targeted therapies benefit from Taiwan's advanced biobank resources and the government's openness to innovative regulatory pathways. This positions Taiwan as a strategic Asia-Pacific hub for precision medicine clinical development as well as commercialization.
Everything in Your Engagement
Every Taevas Global legal representation engagement for Taiwan pharmaceuticals includes these eight core deliverables, providing end-to-end coverage from appointment through ongoing compliance.
Legal Representative Appointment Package
Complete preparation, notarization coordination, and TFDA filing of all documents required to appoint Taevas Global as your registered legal representative in Taiwan, including power of attorney and authorization letters.
Regulatory Pathway Assessment Report
A written report identifying the correct TFDA registration pathway for each product in your Taiwan portfolio, including classification, applicable guidelines, estimated timelines, and a documentation gap analysis.
CTD Dossier Review and Preparation
Comprehensive review of your existing CTD modules against current TFDA requirements, followed by preparation or remediation of all sections needed for a complete and compliant drug registration submission.
TFDA Submission Management
End-to-end management of your drug registration submission through TFDA's online portal, including fee payment, status tracking, deficiency letter responses, and direct liaison with TFDA reviewers.
Labeling and Packaging Compliance Review
Detailed review of your proposed Taiwan product labeling and packaging against TFDA requirements for language, content, warnings, and format, with a written compliance report and recommended revisions.
Post-Market Compliance Calendar
A customized compliance calendar covering all post-approval obligations for your Taiwan drug licenses, including renewal dates, pharmacovigilance reporting windows, and post-approval change notification deadlines.
Adverse Event Reporting Service
Ongoing management of all adverse drug reaction reports to TFDA within statutory timelines, including intake triage, causality assessment coordination, and submission of Individual Case Safety Reports (ICSRs).
NHI Reimbursement Strategy Brief
A strategic brief outlining the NHI reimbursement listing process for your products, including pricing benchmarks, required health economic evidence, and recommended positioning for the National Health Insurance Administration review.
Built for These Situations
Foreign Manufacturer Entering Taiwan for the First Time
You have a registered pharmaceutical product in your home market and see Taiwan as a strategic Asia-Pacific expansion opportunity, but you have no existing local entity, no TFDA relationships, and no in-house regulatory affairs capability for Taiwan. The mandatory legal representative requirement under the Pharmaceutical Affairs Act means you cannot even begin the registration process without a qualified local partner. Taevas Global provides the immediate local presence and regulatory expertise you need to move from intent to submission.
After Legal Representation, Most Clients Move To
Common Questions
Ready to Map Your Taiwan Opportunity?
Speak with a Taevas Global regulatory specialist today to assess your Taiwan pharmaceuticals market entry pathway and get a tailored legal representation proposal within 48 hours.